Join the club for FREE to access the whole archive and other member benefits.

Cortexyme

Company developing new therapies for neurodegenerative diseases.

Cortexyme is a clinical stage biopharmaceutical company pioneering a novel disease-modifying therapeutic approach to treat what we believe to be a key underlying cause of Alzheimer’s and other degenerative diseases. Cortexyme is targeting a specific pathogen found in the brain of Alzheimer’s patients that causes neurodegeneration and other pathology in animal models. Cortexyme’s lead small molecule, COR388, has advanced through preclinical and Phase Ib testing and is currently the subject of a Phase 2/3 GAIN clinical trial in mild to moderate Alzheimer’s disease patients.

Visit website: https://www.cortexyme.com/

 cortexyme-inc.

 Cortexyme

Details last updated 29-Nov-2019

Cortexyme News

A new drug against Alzheimer's targets gum disease bacteria

New Scientist - 17-Jul-2019

A different approach to Alzheimer's that may be correct

Read more...

Bacteria causing gum disease may play a role in triggering Alzheimer's

NHS - 24-Jan-2019

Keeping your gum healthy may save you from Alzheimer's disease

Read more...
Topics mentioned on this page:
Laboratory Automation